Hernández-Mitre, María Patricia http://orcid.org/0000-0003-3565-0292
Tong, Steven Y. C. http://orcid.org/0000-0002-1368-8356
Denholm, Justin T. http://orcid.org/0000-0002-9214-6431
Dore, Gregory J. http://orcid.org/0000-0002-4741-2622
Bowen, Asha C. http://orcid.org/0000-0002-3242-1155
Lewin, Sharon R. http://orcid.org/0000-0002-0330-8241
Venkatesh, Balasubramanian http://orcid.org/0000-0003-2893-6954
Hills, Thomas E. http://orcid.org/0000-0003-0322-5822
McQuilten, Zoe http://orcid.org/0000-0001-9698-7185
Paterson, David L. http://orcid.org/0000-0003-2079-4437
Morpeth, Susan C. http://orcid.org/0000-0002-6131-8536
Roberts, Jason A. http://orcid.org/0000-0001-6218-435X
Funding for this research was provided by:
Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007)
Australian National Health and Medical Research Council Investigator Grant (APP2009736)
Advancing Queensland Clinical Fellowship
Australian National Health and Medical Research Council Investigator Award (GNT1175509)
The University of Queensland
Article History
Accepted: 7 August 2022
First Online: 30 August 2022
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions. Jason A. Roberts would like to acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing Queensland Clinical Fellowship. Asha C. Bowen received salary support from the Australian National Health and Medical Research Council Investigator Award (GNT1175509).
: The following authors Steven Y.C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C. Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas E. Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth and Jason A. Roberts are members of the Australasian COVID-19 Trial (ASCOT), which is studying nafamostat as an antiviral treatment for non-critically ill, hospitalised COVID-19 patients. ASCOT has received nafamostat drug and an unrestricted investigator-initiated grant from manufacturer Chong Kun Dang Pharmaceuticals (Seoul, Korea) and Institute Pasteur Korea. ASCOT is supported by the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE), The BHP Foundation, Health Research Council of New Zealand, Hospital Research Foundation, The Macquarie Group Foundation, The Minderoo Foundation, The Pratt Foundation, Royal Brisbane and Women’s Hospital Foundation, The Common Good (The Prince Charles Hospital Foundation), Wesley Medical Research, Chong Kun Dang Pharmaceutical Corporation, NSW Office for Health and Medical Research, Medical Research Future Fund (grant MRF2002132) and the Russell and Womersley Foundation.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the work presented in this manuscript.